Emercell

Emercell is a Paris-based biotech developing NK-001, an off-the-shelf, allogeneic Natural Killer (NK) cell therapy for oncology. The therapy is produced from pooled umbilical cord blood using a patented process and is intended for synergistic use with existing monoclonal antibodies. The company has achieved significant milestones, including IMPD approval to start a clinical trial in 2025, strategic manufacturing partnerships, and selection for the French government's France 2030 initiative, positioning it in the competitive cell therapy landscape with a potentially more accessible product.

Patented platform for producing allogeneic, off-the-shelf Natural Killer (NK) cell therapies from pooled umbilical cord blood (UCB). The process involves activation and ex vivo amplification of NK cells, resulting in a cryopreserved product designed for synergistic use with monoclonal antibodies.

Emercell operates in the highly competitive allogeneic cell therapy arena, facing off against numerous biotechs and pharma companies developing engineered NK and T-cell platforms. Competitors often employ genetic modification for enhanced persistence or targeting. Emercell's differentiation lies in its pooled, unmodified UCB source and focus on antibody synergy, aiming for a potentially simpler and more cost-effective product.